• Anti-InflammatoryEnrolling

  Study to evaluate BI 1291583 in adults with bronchiectasis , protocol number BI 1397-0014 (Airtivity)

  This study will test the effectiveness, safety, and tolerability of BI 1291583, a drug intended to reduce inflammation in the lungs.

  • Age:

    12 Years and Older

  • Mutation(s):

    No Mutation Requirement

  • FEV1% Predicted:

    50 to 100%

  • Number of Visits:

    9

  • Length of Participation:

    76 weeks

• Anti-InflammatoryClosed to Enrollment

  Study to evaluate BI 1291583 in adults with cystic fibrosis bronchiectasis. (Clairafly) , protocol number Boehringer Ingelheim BI1397-0013

  BI 1291583 is a potential therapy intended to reduce inflammation in the lungs of people with bronchiectasis, the progressive lung disease that occurs in cystic fibrosis and other conditions. This study will test the safety, tolerability, and the effect on the body of BI 1291583. 

  • Age:

    18 Years and Older

  • Mutation(s):

    No Mutation Requirement

  • FEV1% Predicted:

    No FEV1 Limit

  • Number of Visits:

    7

  • Length of Participation:

    22 weeks

Studies in this tool are multi-center studies facilitated by the Cystic Fibrosis Therapeutics Development Network. For a complete list of cystic fibrosis related studies, visit www.clinicaltrials.gov.